Floatz logo

ETOPOSIDE

Primary CNS Lymphoma

Federal Research Institute of Pediatric Hematology, Oncology and ImmunologySmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

73 Active assets in the Primary CNS Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Ono Pharmaceutical Co., Ltd.
Phase 4BBB
METHOTREXATE
Assistance Publique Hopitaux De Marseille
Phase 4BB
Inno-206
Juan P. Alderuccio, MD
Phase 4BB
Idarubicine
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BB
Orelabrutinib
The First Affiliated Hospital with Nanjing Medical University
Phase 3BB

View all 50 →

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →